Repository logo
 

Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Wijeyekoon, Ruwani S 
Moore, Sarah F 
Farrell, Krista 
Breen, David P 
Barker, Roger A 

Abstract

INTRODUCTION: Immune markers are altered in Parkinson's disease (PD), but relationships between cerebrospinal fluid (CSF) and plasma cytokines and associations with neurodegeneration-associated proteins remain unclear. METHODS: CSF and plasma samples and demographic/clinical measures were obtained from 35 PD patients. CSF samples were analyzed for cytokines (together with plasma) and for α-synuclein, amyloid β(1-42) peptide, total tau, and phospho(Thr231)-tau. RESULTS: There were no CSF-plasma cytokine correlations. Interleukin (IL)-8 was higher and interferon-γ, IL-10, and tumor necrosis factor-α were lower in CSF versus plasma. In CSF, total tau correlated positively with IL-8 and IL-1β, whereas α-synuclein correlated positively with amyloid β(1-42) and negatively with semantic fluency (a known marker of PD dementia risk). DISCUSSION: CSF and peripheral cytokine profiles in PD are not closely related. Associations between CSF IL-8 and IL-1β and tau suggest that CSF inflammatory changes may relate to tau pathology within PD. CSF α-synuclein/amyloid β may reflect the risk of developing PD dementia. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Description

Keywords

Parkinson's disease, alpha-synuclein, cerebrospinal fluid, cytokine, tau, Amyloid beta-Peptides, Biomarkers, Cytokines, Humans, Parkinson Disease, Peptide Fragments, alpha-Synuclein, tau Proteins

Journal Title

Mov Disord

Conference Name

Journal ISSN

0885-3185
1531-8257

Volume Title

35

Publisher

Wiley

Rights

All rights reserved
Sponsorship
Addenbrooke's Charitable Trust (ACT) (9968 MINUTE NO 24/14B)
Addenbrooke's Charitable Trust (ACT) (PF15/CWG)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Medical Research Council (MR/R007446/1)
Medical Research Council (MC_PC_12009)
Medical Research Council (MC_PC_17230)
European Commission (242003)
Wellcome Trust (203151/Z/16/Z)
Funding for this work was provided by the Rosetrees Trust (M369-F1), Addenbrooke’s Charitable Trust (PF15/CWG) and the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (146281). RSW was supported by a Fellowship from Addenbrooke’s Charitable Trust (RG77199). SFM was supported by the Transeuro EU FP7 grant (242003) and is now an NIHR Academic Clinical Fellow (ACF-2015-23-501). DPB is supported by a Wellcome Trust Clinical Research Career Development Fellowship. RAB is an NIHR Senior Investigator (NF-SI-0616-10011) and is supported by the Wellcome Trust-MRC Cambridge Stem Cell Institute. CHWG holds a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1) and receives support from the Cambridge Centre for Parkinson-Plus.